Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has identified Pim kinase inhibitors reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have synthesized annulated 2-amino-3-cyano thiophenes and derivatives acting as KRAS GTPase and its mutant inhibitors reported to be useful for the treatment of cancer.
Researchers at Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer and more.
Researchers at Boehringer Ingelheim (BI) Pharma GmbH & Co. KG and Vanderbilt University have described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moieties covalently linked to GTPase KRAS (mutant) binding moieties through a linker.
Marvel Biotechnology Inc. has divulged purine compounds acting as adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer, depression, anxiety disorder, multiple sclerosis, nonalcoholic steatohepatitis, scleroderma, Alzheimer’s disease and Parkinson’s disease.
Vertex Pharmaceuticals Inc. has identified 4-phenyl-2-(1H-1,2,3-triazol-4-yl)piperidin-4-ol derivatives acting as apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of pancreatic cancer, focal segmental glomerulosclerosis and renal disorders.
Researchers from Johns Hopkins University and Lieber Institute Inc. have synthesized peripherally and luminally restricted inhibitors of the serotonin transporter (SERT) reported to be useful for disorders of gastrointestinal motility, including the treatment of irritable bowel syndrome (IBS).
Researchers at Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. and Medshine Discovery Inc. have divulged novel non-fluorinated quinolones reported to be useful for the treatment of acne, bacterial infections and inflammatory disorders.